Zacks: Analysts Anticipate Steris PLC (STE) Will Post Earnings of $1.26 Per Share

Wall Street brokerages expect that Steris PLC (NYSE:STE) will report earnings of $1.26 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Steris’ earnings. The highest EPS estimate is $1.30 and the lowest is $1.23. Steris posted earnings per share of $1.12 during the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The company is expected to issue its next quarterly earnings report on Wednesday, February 6th.

According to Zacks, analysts expect that Steris will report full-year earnings of $4.77 per share for the current fiscal year, with EPS estimates ranging from $4.69 to $4.80. For the next year, analysts expect that the firm will post earnings of $5.32 per share, with EPS estimates ranging from $5.25 to $5.47. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Steris.

Steris (NYSE:STE) last posted its earnings results on Tuesday, November 6th. The medical equipment provider reported $1.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.02. Steris had a net margin of 11.72% and a return on equity of 12.15%. The firm had revenue of $679.00 million for the quarter, compared to analysts’ expectations of $659.14 million. During the same quarter last year, the firm earned $0.94 EPS. The company’s quarterly revenue was up 7.1% compared to the same quarter last year.

Several research firms have commented on STE. Zacks Investment Research reissued a “buy” rating and set a $132.00 target price on shares of Steris in a research report on Friday, November 16th. KeyCorp lifted their target price on shares of Steris from $120.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 13th. JMP Securities lifted their target price on shares of Steris from $113.00 to $125.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 9th. Finally, Stephens reissued a “buy” rating and set a $125.00 target price on shares of Steris in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $119.33.

In related news, insider Michael J. Tokich sold 34,500 shares of Steris stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $119.16, for a total value of $4,111,020.00. Following the sale, the insider now owns 64,958 shares of the company’s stock, valued at approximately $7,740,395.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of Steris stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $120.50, for a total transaction of $1,205,000.00. The disclosure for this sale can be found here. Insiders own 2.38% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC raised its holdings in shares of Steris by 118.0% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 909 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 492 shares during the period. First Hawaiian Bank purchased a new position in Steris in the 3rd quarter valued at approximately $106,000. Point72 Hong Kong Ltd purchased a new position in Steris in the 2nd quarter valued at approximately $116,000. Fort L.P. purchased a new position in Steris in the 2nd quarter valued at approximately $121,000. Finally, Parallel Advisors LLC grew its stake in Steris by 480.4% in the 3rd quarter. Parallel Advisors LLC now owns 1,364 shares of the medical equipment provider’s stock valued at $156,000 after buying an additional 1,129 shares in the last quarter. 89.90% of the stock is currently owned by institutional investors.

Shares of Steris stock traded up $0.57 during mid-day trading on Thursday, hitting $113.25. 334,054 shares of the stock were exchanged, compared to its average volume of 468,981. Steris has a 12 month low of $82.88 and a 12 month high of $121.67. The company has a quick ratio of 2.01, a current ratio of 2.63 and a debt-to-equity ratio of 0.41. The stock has a market cap of $9.52 billion, a P/E ratio of 27.29 and a beta of 1.03.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 21st. Investors of record on Wednesday, November 28th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Tuesday, November 27th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.20%. Steris’s dividend payout ratio (DPR) is presently 32.77%.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Recommended Story: What is Cost of Debt?

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply